Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: Susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression

Kautto, Mervi; Kampman, Olli; Mononen, Nina; Lehtimäki, Terho; Haraldsson, Susann; Koivisto, Pasi A.; Leìnonen, Esa

doi:10.1016/j.neulet.2015.01.077

Cited by 15 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conclusive results in genetic studies involving ECT have been challenging because of small sample sizes, variations in ethnic group, different end‐point measures, ECT doses/parameters or adjunct anaesthetics and heterogeneous phenotype definitions. Also, several studies (Huuhka et al ., ; Anttila et al ., ; Huuhka et al ., ; Anttila et al ., ; Huuhka et al ., ; Huuhka et al ., ; Anttila et al ., ; Viikki et al ., ; Viikki et al ., ; Viikki et al ., ; Kautto et al ., ) appear to have exploited the same sample for the investigation of different genetic variants not, however, applying correction for multiple testing across studies which in fact would reduce the number of positive findings (Table 1). Importantly, many patients involved in the ECT genetic studies described in this review, more often than not, had received concomitant psychopharmacotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…A haplotype analysis of serotonin 2A (5-HT2A; HTR2A) receptor polymorphisms rs7997012 and rs6311 in 119 patients with TRD revealed no significant association with changes in MADRS score after ECT alone, but the interaction between polymorphisms and gender explained 14% of the variance in MADRS score changes (Viikki et al, 2011). Similarly, a study in 119 Finnish patients with TRD showed that patients with the combined 5-HTTLPR ll and norepinephrine transporter (NET) 182TT (rs2242446) genotypes displayed a poorer treatment response to ECT (Kautto et al, 2015).…”

Section: Serotonin-and G Protein-related Genesmentioning

confidence: 99%

See 1 more Smart Citation

Genetic mechanisms of electroconvulsive therapy response in depression

Benson-Martin

Stein

Baldwin

et al. 2016

Human Psychopharmacology

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is known to be one of the most effective treatments for managing depression and other severe mental illnesses. Nevertheless, the exact mechanisms underlying response to ECT remain uncertain. This mini-review presents clinical findings regarding the role of genetic factors in the aetiology of the ECT response. Studies on the role of variation in the catechol-O-methyltransferase (COMT) gene; other dopamine-, serotonin-, and G-protein-related genes; brain-derived neurotrophic factor (BDNF); apolipoprotein E (APOE); angiotensin I-converting enzyme (ACE) and vascular endothelial growth factor (VEGF) genes in mediating response to ECT are summarized. The existing data support the notion that some genetic factors-particularly the functional COMT val158met polymorphism-may play a role in the magnitude of clinical response to ECT, and thus could serve as potential biomarkers for future personalized treatment approaches. However, much of the work to date is preliminary, and large-scale confirmatory studies are still needed. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Serotonin-and G Protein-related Genesmentioning

confidence: 99%

Genetic mechanisms of electroconvulsive therapy response in depression

Benson-Martin

Stein

Baldwin

et al. 2016

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET182C) polymorphisms have been suggested to be associated with ECT treatment response. 81) However, studies conducted on rodents in past using radio-ligands or measuring serotonin (5-hydroxytryptamine; 5-HT) release have provided ambiguous results regarding effect of ECS on receptor sensitivity. 82) Findings of human studies measuring post ECT blunting of cortisol response over 5-HT 1A receptor agonist treatment were also contradicting.…”

Section: Main Subjectsmentioning

confidence: 99%

How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms

Singh

Kar

2017

Clin Psychopharmacol Neurosci

138

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is a time tested treatment modality for the management of various psychiatric disorders. There have been a lot of modifications in the techniques of delivering ECT over decades. Despite lots of criticisms encountered, ECT has still been used commonly in clinical practice due to its safety and efficacy. Research evidences found multiple neuro-biological mechanisms for the therapeutic effect of ECT. ECT brings about various neuro-physiological as well as neuro-chemical changes in the macro- and micro-environment of the brain. Diverse changes involving expression of genes, functional connectivity, neurochemicals, permeability of blood-brain-barrier, alteration in immune system has been suggested to be responsible for the therapeutic effects of ECT. This article reviews different neurobiological mechanisms responsible for the therapeutic efficacy of ECT.

show abstract

“…Forty seven of the 89 were observational studies (Azuma et al, 2011;Bär et al, 2010;Bayless et al, 2010;Beall et al, 2012;Bersani et al, 2014;Bilgen et al, 2014;Burgese & Bassitt, 2015;Casarotto et al, 2013;Chiaie et al, 2013;Dannlowski et al, 2013;Dukart et al, 2014;Ebert et al, 2010;Galletly, Paterson, & Burton, 2012;Goto et al, 2012;Guloksuz et al, 2015;Hu et al, 2010;Johansson, Ehnvall, Friberg, & Myredal, 2010;Joshi et al, 2015;Kalogerakou et al, 2015;Kautto et al, 2015;Lin et al, 2013;Loo, Mahon, Katalinic, Lyndon, & Hadzi-Pavlovic, 2011;Lucca et al, 2010;Lyden et al, 2014;McCall et al, 2013;Medda et al, 2014;Meeter, Murre, Janssen, Birkenhager, & van den Broek, 2011;Minelli et al, 2014;Nickl-Jockschat et al, 2015;Nordanskog, Larsson, Larsson, & Johanson, 2014;Ota et al, 2015;Oudega et al, 2011;Perrin et al, 2012;Piccinni et al, 2013;Rapinesi et al, 2015;Rapinesi et al, 2013;Royster et al, 2012;Saijo et al, 2010;Samuelsson, Gerdin, Öllinger, & Vrethem, 2012;Tendolkar et al, ...…”

Section: Focus and Design Of The 91 Studiesmentioning

confidence: 99%

Is Electroconvulsive Therapy for Depression More Effective Than Placebo? A Systematic Review of Studies Since 2009

Read

Arnold

2017

Ethical Hum Psychol Psychiatry

View full text Add to dashboard Cite

Is electroconvulsive therapy for depression more effective than placebo? A systematic review of studies since 2009. ABSTRACTBackground: A 2010 review of studies and previous reviews and meta-analyses found minimal evidence that ECT for depression was more effective than placebo during the treatment period and no evidence at all of efficacy beyond the end of treatment. The current review explored whether any contradictory evidence has since been generated. Method: MEDLINE and PsycINFO were searched to identify all post 2009 studies that had compared ECT and simulated ECT for depression, or had in any other way generated valid depression data for ECT recipients at two or more points in time. Results: Ninety-one studies met inclusion criteria. There were no new placebo-controlled trials. There have now been no such studies since 1985. Only four placebo-controlled studies have ever produced data beyond the end of treatment, none of which had found any advantage for ECT over placebo. Of the 91 studies only two aimed to evaluate the efficacy of ECT. Both were severely flawed. None of the other 89 produced robust evidence that ECT is effective for depression, primarily because at least 60% maintained ECT participants on medication and 89% produced no meaningful follow up data beyond the end of treatment. No studies investigated whether ECT prevents suicide. Conclusions: There is still no evidence that ECT is more effective than placebo for depression reduction or suicide prevention. Given the 1 well-documented high risk of persistent memory dysfunction, the cost-benefit analysis for ECT remains so poor that its use cannot be scientifically, or ethically, justified.

show abstract

Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: Susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression

Cited by 15 publications

References 32 publications

Genetic mechanisms of electroconvulsive therapy response in depression

Genetic mechanisms of electroconvulsive therapy response in depression

How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms

Is Electroconvulsive Therapy for Depression More Effective Than Placebo? A Systematic Review of Studies Since 2009

Contact Info

Product

Resources

About